ALK Antibody (C-term Y1604) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9UM73 |
---|---|
Clone Names | 100813002 |
Gene ID | 238 |
---|---|
Other Names | ALK tyrosine kinase receptor, Anaplastic lymphoma kinase, CD246, ALK |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ALK {ECO:0000303|PubMed:9174053, ECO:0000312|HGNC:HGNC:427} |
---|---|
Function | Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150). |
Cellular Location | Cell membrane; Single-pass type I membrane protein Note=Membrane attachment is essential for promotion of neuron-like differentiation and cell proliferation arrest through specific activation of the MAP kinase pathway. |
Tissue Location | Expressed in brain and CNS. Also expressed in the small intestine and testis, but not in normal lymphoid cells |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The 2;5 chromosomal translocation is frequently associatedwith anaplastic large cell lymphomas (ALCLs). The translocationcreates a fusion gene consisting of the ALK (anaplastic lymphomakinase) gene and the nucleophosmin (NPM) gene: the 3' half of ALK,derived from chromosome 2, is fused to the 5' portion of NPM fromchromosome 5. A recent study shows that the product of the NPM-ALKfusion gene is oncogenic. The deduced amino acid sequences revealthat ALK is a novel receptor protein-tyrosine kinase having aputative transmembrane domain and an extracellular domain. Thesesequences are absent in the product of the transforming NPM-ALKgene. ALK shows the greatest sequence similarity to LTK (leukocytetyrosine kinase). ALK plays an important role in the development ofthe brain and exerts its effects on specific neurons in the nervoussystem.
References
Ardini, E., et al. Cancer Lett. 299(2):81-94(2010)Ohira, M., et al. Cancer Sci. 101(11):2295-2301(2010)Merkel, O., et al. Proc. Natl. Acad. Sci. U.S.A. 107(37):16228-16233(2010)De Brouwer, S., et al. Clin. Cancer Res. 16(17):4353-4362(2010)Bossi, R.T., et al. Biochemistry 49(32):6813-6825(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.